Rankia USA Rankia Argentina Rankia Brasil Rankia Chile Rankia Colombia Rankia Czechia Rankia Deutschland Rankia España Rankia France Rankia Indonesia Rankia Italia Rankia Magyarország Rankia México Rankia Netherlands Rankia Perú Rankia Polska Rankia Portugal Rankia Romania Rankia Türkiye Rankia United Kingdom
Acceder

Farmas USA

135K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
13,670 / 16,979
#109353

Re: Farmas USA

SESN

Pues mira, me he animado y he pillado mil cromos... así la sigo más de cerca.

#109355

Re: Farmas USA

No pude postear antes. Un minuto antes del cierre de sesion, dentro a 11,97

TGTX

#109356

Re: Farmas USA

La estaba mirando ...

Tiene a su MM50 semanal en 12 y la MM200 diaria en 11,84 para defender este nivel.

Apetecible por la zona en la que esta el precio pero por indicadores no me mola, tiene inercia bajista ... 

Yo me voy a esperar a ver que hace, teoricamente aun le quedan unas cuantas sesiones a MACD para volver a rearmarse e irse al verde ... 

TGTX

#109358

Re: Farmas USA

TGTX

Espero tengáis en cuenta que para este verano (a finales en principio) deberían sacar resultados fase 3 UNITY-CLL. No es un evento menor...para lo bueno o para lo malo

#109360

Re: Farmas USA

CBIO

Sigo montada en la ola... Conociendo lo ilíquida que es y cómo se menea, debería tener un short-squeeze hasta cerrar el gap. Puede que se desinfle en pre, pero suele recuperar. (No me seáis escépticos, que el 28 de marzo del año pasado se cascó un 200% de golpe).

Positive Interim Data from a Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors

our subcutaneous FVIIa variant MarzAA for the treatment of hemophilia A or B with inhibitors,” said Nassim Usman, Ph.D., chief executive officer of Catalyst. “The interim results from the Phase 2/3 trial support our target of achieving significant reductions in annualized bleed rate with daily subcutaneous injections of MarzAA. We expect to open more trial sites and increase enrollment as the year progresses and plan to complete the Phase 2 portion of the Phase 2/3 study by the end of 2018.”

Dr. Howard Levy, chief medical officer of Catalyst, presented the interim results from the MarzAA Phase 2/3 trial in which five of 12 subjects have been enrolled. One subject, with a historical annualized bleed rate (ABR) of 26.7, has completed the study with one bleed during 96 days of prophylaxis. The subject experienced no bleeds during treatment with 60 µg/kg MarzAA for 50 days and one bleed at Day 46 during treatment with 30 µg/kg MarzAA. Two other subjects with ABRs of 15.9 and 16.6 are currently in the first 50 days of dosing. MarzAA’s intravenous (IV) half-life of 3.5 hours was increased to 9.5 hours when dosed subcutaneously. Through a cumulative 160 dosed days, no anti-drug antibodies to MarzAA have been detected to date.

Dr. Levy also presented the most current data from the CB 2679d/ISU304 Phase 1/2 trial. In Cohort 6, two subjects have been enrolled and achieved FIX trough activity levels >30% with one IV dose followed by 9 daily SQ doses. The two subjects, who were cousins, developed neutralizing antibodies (nAbs) to CB 2679d. The nAb was transient in subject C5-01-S02 and was below the level of quantification at a follow up visit. The nAb in subject C5-01-S01 fell below 1 Bethesda Unit at a follow up visit. The nAbs bind to CB 2679d, but not to wildtype FIX. Both Cohort 6 subjects returned to their prior prophylaxis treatment (BeneFIX® or RIXUBIS) with continued efficacy.

 

 

https://globenewswire.com/news-release/2018/07/18/1538789/0/en/Catalyst-Biosciences-Announces-Positive-Interim-Data-from-a-Phase-2-3-Study-of-Marzeptacog-Alfa-Activated-in-Individuals-with-Hemophilia-A-or-B-with-Inhibitors.html

«Después de nada, o después de todo/ supe que todo no era más que nada.»

Te puede interesar...

- No hay entradas a destacar -

- No hay entradas a destacar -

Brokers destacados